In this talk, James Zoum, PhD explores how generative AI agents can enable drug discovery and development. He introduces the Virtual Lab—a collaborative team of AI scientist agents conducting in silico research meetings to tackle open-ended R&D projects. The Virtual Lab designed new nanobody binders to recent COVID variants, which were experimentally validated. He then discusses some interesting opportunities in designing and optimizing multi-agent interactions.
Presenter
James Zou, PhD
Stanford University